To determine the efficacy and safety of high-frequency oscillatory ventilation (HFOV) compared to conventional ventilation (CV) for the treatment of respiratory failure in term and near-term infants in Colombia.
INTRODUCTION
Conventional mechanical ventilation (CV) may produce large fluctuations in alveolar pressure and thoracic gas volume, and, therefore, may predispose the diseased lung to both barotrauma and volutrauma, with a subsequent risk of developing chronic lung disease (CLD). 1, 2 In animal models of respiratory disease, highfrequency oscillatory ventilation (HFOV) decreases lung injury, as compared to CV, presumably by decreasing fluctuations in alveolar pressure with the use of small tidal volumes (less than the anatomic dead space). [3] [4] [5] It is not known whether the reduction of lung injury observed in these animal models can be reproduced in the neonate with respiratory disease. However, most centers in the United States use HFOV as a primary therapy for infants with severe lung disease, or more commonly as rescue therapy for selected infants who fail CV. [6] [7] [8] [9] In Colombia, and other countries in which health care resources are scarce, HFOV is either unavailable or available in a very limited number of centers. Investment in this expensive technology is often contemplated because of the perceived benefits of this therapy. We designed a randomized controlled trial to assess whether the benefits of the early use of HFOV improves outcomes in term and near-term infants in the context of neonatal intensive care in Colombia to a degree that would justify the expenditure to acquire this technology.
METHODS

Organization and Eligibility Criteria
This study was conducted in five neonatal intensive care units in Colombia. Participating centers would be categorized as either IIIA or IIIB special care nurseries. 10 HFOV was not available in any of the centers prior to the trial, although some of the attending physicians had prior experience with its use. To minimize the effect of inexperience with HFOV, workshops were conducted and at least five infants were treated with HFOV in each center before study enrollment. A site principal investigator with expertise in the use of HFOV served as a consultant for all participating centers. Prior to the interim analysis, inhaled nitric oxide became available in two centers following the Food and Drug Administration approval in the United States. Extracorporeal membrane oxygenation was not available at any time during the study period. This study was approved by the institutional review boards at the University of North Carolina and participating centers.
Eligible infants were those born at >35 weeks gestation with birth weight Z1750 g. All infants required mechanical ventilation for respiratory failure with an anticipated duration of ventilation >24 hours, and enrolled at a postnatal age between 4 and 48 hours. Respiratory failure was defined as the requirement of at least 60% oxygen to maintain a saturation by pulse oximetry >90% and PaO 2 Z60 mmHg on two consecutive arterial blood gases collected at least 30 minutes, but not more than 2 hours apart. To avoid prolonged exposure to CV before randomization, enrollment had to occur within 8 hours of satisfying eligibility criteria.
Exclusion criteria included major congenital anomalies, multiple gestation birth, and the presence of pulmonary air leak prior to enrollment. Patients suspected of having a congenital heart anomaly or persistent pulmonary hypertension (PPHN) had an echocardiogram prior to confirmation of eligibility.
Study Design
Study personnel screened all newborn infants requiring mechanical ventilation to determine eligibility. After written parental consent, the attending physician assigned a presumptive cause of respiratory failure, and infants were randomly allocated to treatment using sealed, opaque envelopes. Randomization was stratified by center and by presumptive cause of respiratory failure (three strata: parenchymal lung disease (respiratory distress syndrome or pneumonia/sepsis), meconium aspiration syndrome, and PPHN). Patients with severe hypoxemia, decreased pulmonary vascular markings on chest radiograph, and evidence of right-to-left shunting without structural abnormality of the heart were assigned a presumptive diagnosis of PPHN.
After enrollment, infants were managed on each ventilator modality according to predetermined algorithms. Infants in the CV group remained on CV until they met criteria for treatment failure or were extubated. Infants in the HFOV group remained on this mode of ventilation until they met criteria for treatment failure or until their ventilator support reached a pre-determined level that predicted imminent extubation, at which time they were placed on CV.
Infants in the CV group were treated with time-cycled, pressurelimited ventilators; none had the capability of monitoring tidal volume. Infants in the HFOV group were managed with the SensorMedics 3100A ventilator (SensorMedics Corp., Yorba Linda, CA).
Ventilation Strategies
Ventilation strategies for both groups were standardized across centers. Hypoxemia occurring during CV was managed by increasing oxygen concentration when the fraction of inspired oxygen (FiO 2 ) was <0.40, or by increasing the mean airway pressure (Paw) with increases in peak inspiratory pressure (PIP) and/or positive end-expiratory pressure when the FiO 2 was >0.40. Carbon dioxide elimination was managed by manipulation of PIP or ventilator rate (not exceeding 80 breaths per minute). Inspiratory time was decreased concurrently with increases in ventilator rate to maintain an inspiratory to expiratory ratio of 1:2.
Initial settings on HFOV included an inspiratory time of 0.33, Paw 2 cmH 2 O above the Paw on CV at the time of enrollment, frequency of 10 Hz, and amplitude adjusted to obtain visual vibration of the chest wall and desired levels of PaCO 2 . Hypoxemia was initially managed with increments of 1 cmH 2 O in Paw if optimal lung inflation was not achieved. If optimal, then FiO 2 was increased to achieve the desired oxygenation.
The aim of both groups was to achieve blood gas values and oxygen saturation within a target range (preductal SpO 2 88 to 94%; PaO 2 60 to 80 mmHg; PaCO 2 without pulmonary interstitial emphysema (PIE) 45 to 55 mmHg, with PIE or CLD 55 to 65 mmHg; pH without PPHN 7.25 to 7.35, with PPHN 7.45 to 7.55) and optimal lung inflation as defined radiographically. Chest radiographs were performed immediately after intubation and at predetermined intervals. Optimal inflation was achieved when the top margin of the right hemidiaphragm was located between the bottom of the eighth rib and the interspace between the ninth and 10th posterior ribs. If pulmonary interstitial emphysema developed, a low lung volume strategy was adopted (diaphragm level between seventh and eighth ribs), and the target range for blood gases and oxygen saturation was modified. Infants in HFOV group were changed to CV when the FiO 2 and Paw were below 0.3 and 9, respectively. Infants in both groups were extubated when the FiO 2 and Paw were below 0.3 and 8, respectively. Crossover to the alternate arm of the study was limited to two circumstances:
1. Within the first 3 hours after enrollment, patients assigned to the HFOV group who experienced a persistent reduction in SpO 2 of greater than 20% of their baseline SpO 2 , were crossed over to CV. This constituted early treatment failure. 2. Patients assigned to either mode of ventilation who developed intractable pulmonary air leak despite 48 hours of a low lung volume strategy, or who in the course of a low lung volume strategy developed severe hypoxemia, were treated with the alternate mode of ventilation. This constituted late treatment failure. Crossover for this indication could occur at any time.
Other aspects of patient management, including fluid and blood pressure management, the use of paralytic agents and sedatives, and nutritional support, were standardized by common protocols. Cranial ultrasounds were performed on all patients within the first five days after enrollment and again at 28 days of life or prior to discharge.
Primary and Secondary Outcomes
Our primary outcome was the combined outcome of neonatal death or pulmonary air leak (PAL). This end point was chosen because these were historically the most common serious consequences of respiratory failure in this population. Secondary outcomes included CLD (need for supplemental oxygen at 28 days of life), grade 3 and 4 intraventricular hemorrhage, 11 periventricular leukomalacia, duration of mechanical ventilation, length of hospitalization and incidence of treatment failure.
Statistical Methods
Sample size calculations were based on the primary outcome. The incidence of this combined outcome was estimated to be 35% based on data obtained from the participating centers during the preceding year to the initiation of the study. We estimated that the use of HFOV would reduce the incidence of this outcome to 17%. A sample size of 200 infants, 100 in each group, was necessary to demonstrate this reduction with an alpha of 0.05 and a beta of 0.1. Statistical analyses were performed using exact nonparametric tests for two sample populations or for 2 Â n contingency tables, and if tests between means were appropriate the two sample t-test was used. All data were analyzed according to original group assignment.
A Safety Review Committee monitored the primary outcome and central nervous system morbidity. An interim analysis was planned after enrollment of the first 100 patients. At the time of this analysis, the Safety Review Committee was instructed to use the observed incidence of the primary outcome in the CV group to reassess the sample size necessary to establish a 50% reduction in this outcome at a level of p<0.05 and a power of 80%.
RESULTS
Patients were enrolled from July 1998 to July 2002. A total of 183 infants met eligibility criteria; 64 infants were excluded because transfer to another institution was anticipated, the parents declined consent, or HFOV was not available at randomization. A total of 119 infants were randomized (55 to HFOV; 64 to CV). The data collection sheets and medical records of one infant in the HFOV group who survived until discharge were lost.
The demographic and clinical characteristics of the study infants are listed in Supplemantary Table 1 . Patients in both groups were similar with respect to birth weight, gestational age, gender, Apgar scores, and baseline prenatal and early postnatal clinical characteristics. Groups were similar with respect to presumptive cause of respiratory failure. A total of 99 infants (84%) were assigned a presumptive diagnosis of parenchymal lung disease (82 infants were treated for sepsis/pneumonia), 11 (9%) meconium aspiration syndrome, and 7 (6%) PPHN. Respiratory parameters prior to enrollment were similar between groups and clinically compatible with moderate to severe respiratory failure. Table 1 lists the primary and secondary outcomes. The incidence of the primary outcome in the CV group dropped significantly to 3.1%. Although more infants in the HFOV group developed the primary outcome, this difference was not significant. Deaths were also higher in this group, but the difference was not significant. Overall neonatal mortality was 5%. Two infants in the HFOV group developed pneumothorax and pneumomediastinum respectively, and one infant in the CV group developed PIE.
Groups were similar with respect to the incidence of chronic lung disease, central nervous system morbidity, duration of mechanical ventilation, and duration of hospitalization. There were two early treatment failures and two late treatment failures in the HFOV group and none in the CV group. Only three infants received inhaled nitric oxide; all were randomized to HFOV.
All deaths occurred within the first 2 weeks of life (Table 2) . One death in the HFOV group resulted from total anomalous pulmonary venous return diagnosed after enrollment, and was included in the analysis as an intention to treat. Two deaths in the HFOV group were early treatment failures that crossed over to CV.
The study was terminated after the interim analysis due to lack of evidence of differences in the primary outcome. An estimated 1558 subjects per group would have been necessary to reduce the frequency of the primary outcome from 3.2 to 1.6%. It would not have been feasible to conduct a study of this size.
DISCUSSION
Based on our initial sample size calculations, this study did not show a significant advantage of HFOV over CV in term and nearterm infants with moderate to severe respiratory failure. Previous studies using HFOV as a rescue therapy in this age group have shown similar results and are difficult to interpret because of the small sample size, not standardizing management on conventional ventilation, high crossover rates, or the confounding effects of therapies such as inhaled nitric oxide or extracorporeal membrane oxygenation. [6] [7] [8] [9] In addition, patients in these studies were usually exposed to prolonged periods of CV, with the potential for lung damage, prior to enrollment, making it difficult to isolate the effects of mode of ventilation. We attempted to minimize the impact of these confounders. Infants were enrolled soon after eligibility criteria were met (within 2 hours), limiting their exposure to CV with high concentrations of oxygen prior to HFOV. Crossover was limited (<5%), management on conventional ventilation and general patient care were standardized, extracorporeal membrane oxygenation was unavailable, and inhaled nitric oxide became available only late in the study. Nonetheless, we did not demonstrate superiority of HFOV compared to CV in this population. All patients enrolled in this trial had the potential to develop severe respiratory failure and meet criteria for NO and/or ECMO rescue therapy. The fact that patients in both groups died without the potential benefits of these expensive rescue therapies supports this statement.
An alternate explanation for our results may have been a lack of experience in the use of HFOV. We attempted to minimize the impact of this potential confounder through intensive preparatory training, the use of treatment algorithms, and the availability of a 24 hours clinical consultant who was an expert in the use of HFOV. Another explanation may be the low rates of mortality and morbidity observed, particularly air leak, in the CV group, handicapping our ability to detect small differences in the outcome. These rates were considerably lower than predicted in our population based on historical data and are reasonably attributable to the preparatory training and standardization of care. 12, 13 Prior to the initiation of the study, CV management protocols varied significantly among study centers and PAL was a frequent clinical event. The use of mild permissive hypercapnea 14 was not considered a standard of care among participating centers. This HFOV  39  3000  13  15  MAS  HFOV  40  2400  15  3  ETF  MAS  HFOV  40  2500  18  3  TAPVR  HFOV  38  2540  14  2  ETF  Pneumonia  HFOV  36  2600  16  7  PPHN  CV  36  2600  15  9  Sepsis HFOV, high-frequency oscillatory ventilation; CV, conventional ventilation; Paw, mean airway pressure at the time of death; TF, treatment failure; ETF, early treatment failure; MAS, meconium aspiration syndrome; PPHN, persistent pulmonary hypertension of the newborn; TAPVR, total anomalous pulmonary venous return.
may explain in part the high incidence of the primary outcome prior to initiating the study. Not standardizing the use of CV may have kept the incidence of the primary outcome at the estimated level, but would have constituted a major limitation in study design. The results of this trial suggest that standardization of ventilator management and general patient care may have a greater effect on morbidity and mortality in Colombia than the mode of ventilation. It is also possible that HFOV may be superior in the treatment of certain diseases (e.g. meconium aspiration syndrome) in which lung recruitment is unsuccessful during CV. 15, 16 We would have been unable to demonstrate the potential advantages of HFOV in these diseases because they were underrepresented in our study population. Mortality was higher, but not significant in the HFOV group. Although our study design minimized crossover, two deaths followed crossover from initial assignment to HFOV, and the infants died on CV. We did not observe significant differences in central nervous system morbidity between groups, although differences in morbidity diagnosed late in the neonatal period may have been masked by excess mortality in the HFOV group. Owing to our relatively small sample size, we cannot exclude the possibility of a harmful effect from exposure to HFOV. Even with the previous limitations, our study represents the largest trial published to date evaluating HFOV in this age group.
Our study is the first trial to use HFOV as an early therapy for respiratory failure without the confounding effects of ECMO and iNO. Results from this trial suggest that when conventional therapies are optimal, in the setting of typical neonatal intensive care in Colombia, HFOV appears to offer no additional advantage compared to CV in the treatment of term or near-term infants with moderate to severe respiratory failure. Although our study was not designed to test the effects of participation in a clinical trial, we hypothesize that standardization of ventilator management and general patient care may have a greater impact on outcome than mode of ventilation, and may be a more cost-effective alternative for countries with limited resources for health care. Results from our study are relevant to both developed and developing countries.
